Containment Genetics In-Vivo Pharma Companies 
Pharmaceutical Technology
MAY 24, 2023
The ability to modify or introduce genetic material in human cells in such a precise and patient-centered manner clearly constitutes a breakthrough in personalized medicine. CGT drugs fall into two major categories: autologous and allogeneic. What are the general differences in the supply chain of CGT vs. traditional clinical trials?
Drug Discovery World
NOVEMBER 15, 2022
Developed with the idea of engineering an enzyme called terminal deoxynucleotidyl transferase (TdT), a type of DNA polymerase, these enzymatic DNA synthesis methods are now the focus of dozens of companies. Anita Ramanathan outlines four synthetic biology approaches that are improving and accelerating drug discovery. .
XTalks
AUGUST 17, 2020
To learn more about innovations in the field, Xtalks spoke to Anish Suri, PhD, president and chief scientific officer of Cue Biopharma about the company’s initiatives in the development of immune-based biological compounds for the treatment of cancers and autoimmune diseases. Cell-Based Immunotherapy vs. Immune Biologics.
Expert insights. Personalized for you.
246 
Let's personalize your content